Literature DB >> 28555385

Cytokine storm and sepsis disease pathogenesis.

Benjamin G Chousterman1,2, Filip K Swirski3, Georg F Weber4.   

Abstract

Infectious diseases are a leading cause of death worldwide. Sepsis is a severe clinical syndrome related to the host response to infection. The severity of infections is due to an activation cascade that will lead to an autoamplifying cytokine production: the cytokine storm. Cytokines are a broad category of relatively small proteins (<40 kDa) that are produced and released with the aim of cell signaling. Our understanding of the processes that trigger this tremendous amount of cytokine production has made dramatic progress over the last decades, but unfortunately, these findings could not translate yet into effective treatments; so far, all clinical trials targeting cytokine production or effects failed. This review aims to summarize the pathophysiology of the cytokine storm; to describe the type, effects, and kinetics of cytokine production; and to discuss the therapeutic challenges of targeting cytokines. New promising therapeutic strategies focusing on the endothelium, as a source and a target of cytokines, are described.

Entities:  

Keywords:  Cytokine; Endothelium; Inflammation; Innate immunity; Sepsis

Mesh:

Substances:

Year:  2017        PMID: 28555385     DOI: 10.1007/s00281-017-0639-8

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  124 in total

1.  Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.

Authors:  Niels C Riedemann; Thomas A Neff; Ren-Feng Guo; Kurt D Bernacki; Ines J Laudes; J Vidya Sarma; John D Lambris; Peter A Ward
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

Review 2.  Induction of interleukin-1 and interleukin-1 receptor antagonist.

Authors:  C A Dinarello
Journal:  Semin Oncol       Date:  1997-06       Impact factor: 4.929

3.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

4.  A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist.

Authors:  H Schreuder; C Tardif; S Trump-Kallmeyer; A Soffientini; E Sarubbi; A Akeson; T Bowlin; S Yanofsky; R W Barrett
Journal:  Nature       Date:  1997-03-13       Impact factor: 49.962

5.  CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs.

Authors:  Shanshan Cai; Sanjay Batra; Sergio A Lira; Jay K Kolls; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2010-10-11       Impact factor: 5.422

6.  Polymorphisms of genes encoding tumor necrosis factor-alpha, interleukin-10, cluster of differentiation-14 and interleukin-1ra in critically ill patients.

Authors:  Maja Surbatovic; Krasimirka Grujic; Bojana Cikota; Miodrag Jevtic; Nikola Filipovic; Predrag Romic; Natasa Strelic; Zvonko Magic
Journal:  J Crit Care       Date:  2010-02-16       Impact factor: 3.425

7.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

8.  Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

Authors:  R V McCloskey; R C Straube; C Sanders; S M Smith; C R Smith
Journal:  Ann Intern Med       Date:  1994-07-01       Impact factor: 25.391

9.  Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats.

Authors:  H R Alexander; G M Doherty; D J Venzon; M J Merino; D L Fraker; J A Norton
Journal:  Surgery       Date:  1992-08       Impact factor: 3.982

10.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

View more
  318 in total

Review 1.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

2.  Deficiency of the novel high mobility group protein HMGXB4 protects against systemic inflammation-induced endotoxemia in mice.

Authors:  Xiangqin He; Kunzhe Dong; Jian Shen; Guoqing Hu; Jinhua Liu; Xiuhua Kang; Liang Wang; Reem T Atawia; Islam Osman; Robert W Caldwell; Meixiang Xiang; Wei Zhang; Zeqi Zheng; Liwu Li; David J R Fulton; Keyu Deng; Hongbo Xin; Jiliang Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

Review 3.  Role of inflammatory markers in corona virus disease (COVID-19) patients: A review.

Authors:  Jyoti Upadhyay; Nidhi Tiwari; Mohd N Ansari
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-07

Review 4.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

Review 5.  Extracorporeal membrane oxygenation and cytokine adsorption.

Authors:  Thomas Datzmann; Karl Träger
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

6.  CYTL1 Promotes the Activation of Neutrophils in a Sepsis Model.

Authors:  Haiyan Xue; Shu Li; Xiujuan Zhao; Fuzheng Guo; Lilei Jiang; Yaxin Wang; Fengxue Zhu
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

7.  Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis.

Authors:  Jouha Min; Maria Nothing; Ben Coble; Hui Zheng; Jongmin Park; Hyungsoon Im; Georg F Weber; Cesar M Castro; Filip K Swirski; Ralph Weissleder; Hakho Lee
Journal:  ACS Nano       Date:  2018-03-20       Impact factor: 15.881

Review 8.  New Insights into the Immune System Using Dirty Mice.

Authors:  Sara E Hamilton; Vladimir P Badovinac; Lalit K Beura; Mark Pierson; Stephen C Jameson; David Masopust; Thomas S Griffith
Journal:  J Immunol       Date:  2020-07-01       Impact factor: 5.422

9.  Pseudomonas aeruginosa-derived pyocyanin reduces adipocyte differentiation, body weight, and fat mass as mechanisms contributing to septic cachexia.

Authors:  Nika Larian; Mark Ensor; Sean E Thatcher; Victoria English; Andrew J Morris; Arnold Stromberg; Lisa A Cassis
Journal:  Food Chem Toxicol       Date:  2019-05-09       Impact factor: 6.023

10.  Umbilical Cord Blood Mesenchymal Stem Cells Enhance Lipopolysaccharide-Induced IL-10 and IL-37 Production in THP-1 Cells.

Authors:  Ting Zhou; Yan Sun; Yanli Wang; Xiaobing Chen; Luo Zhuo; Lin Bu; Suo Xu; Jiayan Han; Xiaomin Li; Jiaxin Shi
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.